Thrivent Financial For Lutherans Revance Therapeutics, Inc. Transaction History

Thrivent Financial For Lutherans

  • $52.6 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$11.47 - $25.07 $36.4 Million - $79.6 Million
-3,176,775 Reduced 97.83%
70,544 $809,000
Q2 2023

Aug 14, 2023
BUY
$24.7 - $37.61 $30.3 Million - $46.1 Million
1,226,338 Added 60.68%
3,247,319 $82.2 Million
Q1 2023

May 17, 2023
BUY
$18.36 - $35.27 $35.7 Million - $68.7 Million
1,946,680 Added 2619.99%
2,020,981 $65.1 Million
Q4 2022

Feb 08, 2023
BUY
$18.32 - $30.66 $1.36 Million - $2.28 Million
74,301 New
74,301 $1.37 Million

Others Institutions Holding RVNC

# of Institutions
234
Shares Held
82.8M
Call Options Held
680K
Put Options Held
896K
View Full List

About Revance Therapeutics, Inc.

RVNC Quotes by TradingView
  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email